TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06756932: A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,942,936

Rescue Site Savings

+$4,586,736

Unlock Full NCT06756932 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06756932 Rescue Dossier →